Redmile Group, LLC
SEC CIK 1425738 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ATTO | Attovia Therapeutics, Inc. | 10% | 782.9K | $10.20M | — | 3 | 2026-08-06 | 2026-08-06 |
| ATRA | Atara Biotherapeutics, Inc. | Dir | 636.9K | — | — | 2 | 2026-07-22 | 2026-07-22 |
| FATE | FATE THERAPEUTICS INC | Dir, 10% | 0 | $166.0K | — | 5 | 2022-06-09 | 2026-04-20 |
| ADCT | ADC Therapeutics SA | 10% | 12.67M | — | $19.64M | 2 | 2026-03-31 | 2026-03-31 |
| ABSI | Absci Corp | Dir | 8.26M | $30.00M | — | 3 | 2021-07-26 | 2024-06-12 |
| STTK | Shattuck Labs, Inc. | Dir, 10% | 5.62M | — | — | 1 | 2024-03-28 | 2024-03-28 |
| ZYME | Zymeworks Inc. | 10% | 6.08M | $153.3K | — | 2 | 2022-10-13 | 2022-10-13 |
| TRDA | Entrada Therapeutics, Inc. | 10% | 1.95M | $20.00M | — | 2 | 2021-11-02 | 2021-11-02 |
| IVVD | Invivyd, Inc. | 10% | 1.92M | $24.99M | — | 2 | 2021-08-10 | 2021-08-10 |
Most active insiders at ATTO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | WALSH COLIN | Dir | $20.57M | $4.50M |
| 2 | Redmile Group, LLC | 10% | $10.20M | — |
| 3 | Frazier Life Sciences XI, L.P. | 10% | $10.00M | — |
| 4 | venBio Global Strategic Fund IV, L.P. | 10% | $6.50M | — |
| 5 | Sanofi | 10% | $5.10M | — |
| 6 | Deep Track Biotechnology Master Fund, Ltd. | 10% | — | — |
Transactions 22
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-08-07 21:47 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Redmile Group, LLC | 10% | C - Cnv Deriv | — | +782.9K | 782.9K | New | — |
| D | 2026-08-07 21:47 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Redmile Group, LLC | 10% | P - Purchase | $17.00 | +200.0K | 982.9K | +26% | +$3.40M |
| DI | 2026-08-07 21:47 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Redmile Group, LLC | 10% | P - Purchase | $17.00 | +400.0K | 1.18M | +51% | +$6.80M |
| DI | 2026-07-24 21:00 | 2026-07-22 | ATRA | Atara Biotherapeutics, Inc. | Redmile Group, LLC | Dir | M - OptEx | — | +195.2K | 636.9K | +44% | — |
| DI | 2026-07-24 21:00 | 2026-07-22 | ATRA | Atara Biotherapeutics, Inc. | Redmile Group, LLC | Dir | F - Tax | — | -60 | 636.9K | -0.0% | — |
| D | 2026-04-22 21:51 | 2026-04-20 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Dir, 10% | J - Other | $0.00 | -8.98M | 0 | -100% | $0 |
| DI | 2026-04-22 21:51 | 2026-04-20 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Dir, 10% | J - Other | $0.00 | +8.98M | 12.88M | +230% | $0 |
| MI | 2026-04-02 21:00 | 2026-03-31+ | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% | S - Sale | $3.34 | -3.00M | 12.67M | -19% | -$10.02M |
| M | 2026-04-02 21:00 | 2026-03-31+ | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% | S - Sale | $3.34 | -2.88M | 10.27M | -22% | -$9.62M |
| DI | 2024-06-14 | 2024-06-12 | ABSI | Absci Corp | Redmile Group, LLC | Dir | A - Grant | $0.00 | +8,820 | 8.26M | +0.1% | $0 |
| I | 2024-04-01 | 2024-03-28 | STTK | Shattuck Labs, Inc. | Redmile Group, LLC | Dir, 10% | J - Other | $0.00 | -4,425 | 5.62M | -0.1% | $0 |
| I | 2023-12-28 | 2023-12-26 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Dir, 10% | P - Purchase | $3.72 | +44.6K | 13.18M | +0.3% | +$166.0K |
| MI | 2023-12-28 | 2023-12-26 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Dir, 10% | J - Other | $3.72 | 0 | 13.14M | New | $0 |
| AI | 2022-10-18 | 2022-10-13 | ZYME | Zymeworks Inc. | Redmile Group, LLC | 10% | P - Purchase | $5.03 | +30.5K | 6.08M | +0.5% | +$153.3K |
| I | 2022-10-17 | 2022-10-13 | ZYME | Zymeworks Inc. | Redmile Group, LLC | 10% | A - Grant | $5.03 | +30.5K | 6.08M | +0.5% | +$153.3K |
| DI | 2022-06-13 | 2022-06-09 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Dir, 10% | A - Grant | $0.00 | +8,650 | 12.97M | +0.1% | $0 |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Entrada Therapeutics, Inc. | Redmile Group, LLC | 10% | P - Purchase | $20.00 | +1.00M | 1.95M | +105% | +$20.00M |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Entrada Therapeutics, Inc. | Redmile Group, LLC | 10% | C - Cnv Deriv | — | +954.4K | 954.4K | New | — |
| DI | 2021-08-12 | 2021-08-10 | IVVD | Invivyd, Inc. | Redmile Group, LLC | 10% | C - Cnv Deriv | — | +1.92M | 1.92M | New | — |
| DI | 2021-08-12 | 2021-08-10 | IVVD | Invivyd, Inc. | Redmile Group, LLC | 10% | P - Purchase | $17.00 | +1.47M | 3.39M | +77% | +$24.99M |
| DMI | 2021-07-28 | 2021-07-26 | ABSI | Absci Corp | Redmile Group, LLC | Dir | C - Cnv Deriv | — | +6.16M | 6.16M | New | — |
| DI | 2021-07-28 | 2021-07-26 | ABSI | Absci Corp | Redmile Group, LLC | Dir | P - Purchase | $16.00 | +1.88M | 8.03M | +30% | +$30.00M |
Purchase Sale Sale after option exercise All abbreviations